S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SEPN · Septerna, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$40.73
+1.38
(+3.51%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$40.73
$39.53
$41.34
52-WEEK RANGE
$40.73
$17.55
$51.10
What's happening
- SEPN is up 3.51% today, trading at $40.73. — Live quote
- Volume today (13,669) is well below its 3-month average of 430,110. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.29 actual vs. $-0.43 estimated (+33.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SEPN
+41.14%
vs S&P 500
+28.36%
1-YEAR RETURN
SEPN
+75.36%
vs S&P 500
+60.80%
6-MONTH RETURN
SEPN
+57.46%
3-MONTH RETURN
SEPN
+16.83%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.29
Est. $-0.43
BEAT +33.3%
2026-04-26 (Q1 2026)
$-0.19
Est. $-0.42
BEAT +55.3%
2026-01-26 (Q4 2025)
$-0.24
Est. $-0.26
BEAT +7.3%
2025-10-26 (Q3 2025)
$-0.09
Est. $0.81
MISS -111.1%
Valuation Measures & Ratios
Enterprise Value4$1.75B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)18.57
Price / Book73.90
EV4 / Revenue17.72
EV4 / EBITDA—
Profit Margin-24.51%
Operating Margin-44.04%
Return on Equity (ROE8)-6.31%
Return on Assets (ROA9)-4.14%
Avg Volume (3M)430,110
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.51B | $1.09B | $854.5M | $468.8M | $253.3M |
| P/E | -39.33 | -23.32 | -14.57 | -5.62 | -3.49 |
| Price/Sales | 20.13 | 22.56 | 38.83 | 530.34 | 234.13 |
| Price/Book | 3.90 | 2.88 | 2.20 | 1.24 | 0.63 |
| EV/Revenue | 19.00 | 21.08 | 24.29 | 316.18 | 40.00 |
| EV/EBITDA | -25.92 | -15.93 | -7.30 | — | — |
| ROE | -9.91% | -12.36% | -15.09% | -22.08% | -18.14% |
| ROA | -6.76% | -8.21% | -9.67% | -20.07% | -16.73% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,096,190
Change from Prior Settlement+6.99%
% of Float—
Days to Cover (Short Ratio)8.80
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 22375.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +75.4%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -24.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SEPN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.7M | $26.5M | $21.5M | $119.0K | $219.0K | $176.0K | $370.0K | $317.0K |
| Operating income | -$16.8M | -$13.3M | $2.6M | -$29.0M | -$25.9M | -$22.6M | -$18.1M | -$15.5M |
| Net income | -$13.0M | -$8.6M | $8.2M | -$24.8M | -$21.5M | -$20.5M | -$16.5M | -$14.1M |
| EPS (diluted) | $-0.29 | $-0.19 | $0.18 | $-0.56 | $-0.49 | $-8.40 | $-7.03 | $-6.35 |
| EPS (basic) | $-0.29 | $-0.19 | $0.18 | $-0.56 | $-0.49 | $-8.40 | $-7.03 | $-6.35 |
| Operating margin | -$63 | -$50 | $12 | -$24.4K | -$11.8K | -$12.8K | -$4.9K | -$4.9K |
| Net margin | -$49 | -$33 | $38 | -$20.9K | -$9.8K | -$11.7K | -$4.5K | -$4.4K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $566.7M | $569.7M | $596.2M | $606.7M | $415.2M | $434.0M | $456.6M | $174.3M |
| Total liabilities | $180.0M | $191.2M | $214.3M | $217.9M | $37.7M | $33.8M | $36.5M | $37.5M |
| Stockholders' equity | $386.7M | $378.5M | $381.9M | $388.7M | $377.6M | $400.3M | $420.0M | -$87.4M |
| Total current assets | $396.2M | $368.1M | $411.0M | $491.7M | $334.1M | $342.5M | $356.8M | $133.4M |
| Total current liabilities | $79.3M | $78.2M | $86.9M | $75.3M | $15.1M | $10.6M | $12.8M | $13.2M |
| Cash & equivalents | $84.7M | $71.6M | $120.7M | $320.0M | $189.3M | $210.0M | $238.2M | $88.2M |
| Marketable securities (current) | $287.7M | $275.8M | $270.4M | $154.4M | $137.2M | $126.0M | $112.7M | $42.3M |
| Accounts receivable | $12.2M | $10.8M | $10.4M | $8.6M | $151.0K | $250.0K | $171.0K | $210.0K |
| Other current assets | $133.0K | $110.0K | $1.2M | $387.0K | $0 | $52.0K | $239.0K | $241.0K |
| Marketable securities (non-current) | $144.2M | $174.7M | $157.6M | $87.2M | $52.6M | $62.2M | $69.9M | $7.0M |
| Property, plant & equipment | $3.9M | $4.3M | $4.4M | $4.3M | $4.7M | $5.0M | $5.1M | $5.4M |
| Other non-current assets | $1.2M | $773.0K | $816.0K | $501.0K | $300.0K | $277.0K | $267.0K | $3.5M |
| Accounts payable | $4.0M | $7.5M | $10.3M | $3.7M | $6.5M | $4.3M | $3.2M | $6.1M |
| Accrued liabilities | $12.6M | $8.6M | $12.2M | $7.8M | $6.6M | $4.4M | $7.8M | $6.0M |
| Deferred revenue (current) | $60.4M | $59.8M | $62.3M | $61.6M | — | — | $0 | — |
| Other non-current liabilities | $521.0K | $100.0K | $0 | $0 | $2.0K | $27.0K | $33.0K | $191.0K |
| Common stock & paid-in capital | $46.0K | $45.0K | $45.0K | $45.0K | $45.0K | $44.0K | $44.0K | $3.0K |
| Retained earnings | -$188.9M | -$175.9M | -$167.3M | -$156.5M | -$164.7M | -$139.8M | -$118.4M | -$97.7M |
| Accumulated other comprehensive income (loss) | -$1.3M | -$569.0K | $617.0K | $375.0K | $176.0K | $198.0K | $56.0K | $176.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.2M | -$25.6M | -$15.0M | $168.8M | -$20.3M | -$23.3M | -$21.0M | -$16.8M |
| Investing cash flow | $18.4M | -$23.8M | -$185.3M | -$38.4M | -$786.0K | -$4.9M | -$133.2M | -$24.8M |
| Financing cash flow | $16.8M | $333.0K | $1.0M | $263.0K | $339.0K | $66.0K | $304.2M | -$1.3M |
| Free cash flow | -$22.2M | -$26.5M | -$15.1M | $168.8M | -$20.3M | -$23.7M | -$21.6M | -$17.4M |
| Capital expenditures | $0 | $832.0K | $65.0K | $13.0K | $58.0K | $382.0K | $612.0K | $578.0K |
| Depreciation & amortization | $400.0K | $400.0K | $1.2M | $400.0K | $400.0K | $400.0K | $1.1M | $400.0K |
| Share-based compensation | $5.1M | $6.0M | $7.0M | $2.5M | $1.8M | $1.5M | $2.6M | $683.0K |
| Deferred income taxes | — | — | $0 | — | — | — | -$153.0K | -$136.0K |
| Change in accounts receivable | $1.3M | $486.0K | $1.7M | $8.5M | -$99.0K | $79.0K | -$40.0K | $10.0K |
| Change in accounts payable | -$3.5M | -$2.3M | $6.1M | -$2.9M | $2.2M | $1.2M | -$1.7M | $2.8M |
| Purchases of investments | $47.6M | $105.2M | — | $110.0M | $63.8M | $49.7M | $147.6M | $33.6M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $46.0M | $1.1M | $151.0K |
| Operating income | -$68.3M | -$80.8M | $2.1M |
| Net income | -$48.9M | -$71.8M | $4.2M |
| EPS (diluted) | $-1.10 | $-7.26 | $0.29 |
| EPS (basic) | $-1.10 | $-7.26 | $0.29 |
| Operating margin | -$149 | -$7.5K | $1.4K |
| Net margin | -$106 | -$6.7K | $2.8K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $596.2M | $456.6M | $130.9M | — |
| Total liabilities | $214.3M | $36.5M | $20.0M | — |
| Stockholders' equity | $381.9M | $420.0M | -$38.4M | -$44.2M |
| Total current assets | $411.0M | $356.8M | $112.7M | — |
| Total current liabilities | $86.9M | $12.8M | $6.9M | — |
| Cash & equivalents | $120.7M | $238.2M | $88.5M | — |
| Marketable securities (current) | $270.4M | $112.7M | $0 | — |
| Accounts receivable | $10.4M | $171.0K | $151.0K | — |
| Other current assets | $1.2M | $239.0K | $92.0K | — |
| Marketable securities (non-current) | $157.6M | $69.9M | $0 | — |
| Property, plant & equipment | $4.4M | $5.1M | $4.7M | — |
| Other non-current assets | $816.0K | $267.0K | $97.0K | — |
| Accounts payable | $10.3M | $3.2M | $2.6M | — |
| Accrued liabilities | $12.2M | $7.8M | $4.3M | — |
| Deferred revenue (current) | $62.3M | $0 | — | — |
| Other non-current liabilities | $0 | $33.0K | $546.0K | — |
| Common stock & paid-in capital | $45.0K | $44.0K | $3.0K | — |
| Retained earnings | -$167.3M | -$118.4M | -$46.6M | — |
| Accumulated other comprehensive income (loss) | $617.0K | $56.0K | $0 | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | $110.2M | -$67.5M | -$38.7M |
| Investing cash flow | -$229.4M | -$160.6M | $22.1M |
| Financing cash flow | $1.7M | $377.8M | $74.5M |
| Free cash flow | $109.7M | -$69.6M | -$41.6M |
| Capital expenditures | $518.0K | $2.1M | $2.9M |
| Depreciation & amortization | $1.6M | $1.4M | $800.0K |
| Share-based compensation | $8.5M | $3.2M | $1.6M |
| Deferred income taxes | $0 | -$491.0K | $491.0K |
| Change in accounts receivable | $10.2M | $20.0K | $151.0K |
| Change in accounts payable | $6.6M | $723.0K | -$653.0K |
| Purchases of investments | — | $213.4M | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SEPN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-18 to 2026-10-15
Recent transactions
- Insiders have net sold 1,724,361 shares over the last 182 days, across 0 purchases and 21 sales.
- Most recent: Bhatt Elizabeth (President and COO) — Option exercise of 4,000 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)1,724,361 sh(21 txns)
Net Shares-1,724,361
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Bhatt Elizabeth | President and COO | Option exercise | 2026-10-15 | 4,000 |
| Long Daniel D. | SVP, Drug Discovery | Option exercise | 2026-09-01 | 3,333 |
| Third Rock Ventures V, L.P. | Reporting person | Open market sale | 2026-08-12 | 147,059 |
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market sale | 2026-08-12 | 746,500 |
| Shaikhly Samira | Chief People Officer | Option exercise | 2026-06-29 | 2,178 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | Bhatt Elizabeth | President and COO | Option exercise | 4,000 | $6.81 |
| 2026-10-15 | Bhatt Elizabeth | President and COO | Open market sale | 1,094 | $36.87 |
| 2026-10-15 | Bhatt Elizabeth | President and COO | Open market sale | 2,906 | $37.61 |
| 2026-09-01 | Long Daniel D. | SVP, Drug Discovery | Option exercise | 3,333 | $2.76 |
| 2026-09-01 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 3,333 | $37.83 |
| 2026-08-12 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 147,059 | $50.27 |
| 2026-08-12 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 141 | $51.08 |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market sale | 746,500 | $42.50 |
| 2026-08-12 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market sale | 746,500 | $42.50 |
| 2026-08-11 | Bhatt Elizabeth | President and COO | Option exercise | 18,681 | $6.81 |
| 2026-08-11 | Bhatt Elizabeth | President and COO | Option exercise | 6,319 | $2.76 |
| 2026-08-11 | Bhatt Elizabeth | President and COO | Open market sale | 25,000 | $44.00 |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Option exercise | 1,816 | $2.76 |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Option exercise | 1,518 | $2.76 |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 1,000 | $33.98 |
| 2026-08-03 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 2,334 | $34.68 |
| 2026-07-15 | Bhatt Elizabeth | President and COO | Option exercise | 4,000 | $6.81 |
| 2026-07-15 | Bhatt Elizabeth | President and COO | Open market sale | 4,000 | $33.99 |
| 2026-07-01 | Long Daniel D. | SVP, Drug Discovery | Option exercise | 3,333 | $2.76 |
| 2026-07-01 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 2,100 | $34.10 |
| 2026-07-01 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 1,233 | $34.81 |
| 2026-06-29 | Shaikhly Samira | Chief People Officer | Option exercise | 2,178 | $6.81 |
| 2026-06-29 | Shaikhly Samira | Chief People Officer | Open market sale | 2,178 | $35.18 |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Option exercise | 10,529 | $2.76 |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Option exercise | 4,471 | $11.70 |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 8,000 | $35.10 |
| 2026-06-22 | Long Daniel D. | SVP, Drug Discovery | Open market sale | 7,000 | $35.97 |
| 2026-06-12 | Shaikhly Samira | Chief People Officer | Option exercise | 6,250 | $11.70 |
| 2026-06-12 | Shaikhly Samira | Chief People Officer | Open market sale | 6,250 | $35.08 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Option exercise | 4,355 | $1.55 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Option exercise | 943 | $2.76 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Option exercise | 637 | $2.76 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Open market sale | 1,700 | $27.78 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Open market sale | 1,346 | $28.79 |
| 2026-06-01 | Shaikhly Samira | Chief People Officer | Open market sale | 2,889 | $29.66 |
| 2026-05-26 | Shaikhly Samira | Chief People Officer | Option exercise | 11,798 | $6.81 |
| 2026-05-26 | Shaikhly Samira | Chief People Officer | Open market sale | 11,798 | $30.06 |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Option exercise | 4,000 | $6.81 |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Open market sale | 2,573 | $23.76 |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Open market sale | 1,101 | $25.24 |
| 2026-04-15 | Bhatt Elizabeth | President and COO | Open market sale | 326 | $25.86 |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Option exercise | 53,714 | $1.55 |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Option exercise | 11,638 | $2.76 |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Option exercise | 5,101 | $2.76 |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Open market sale | 4,090 | $27.51 |
| 2026-03-02 | Shaikhly Samira | Chief People Officer | Open market sale | 66,363 | $28.14 |
| 2026-02-18 | Bhatt Elizabeth | President and COO | Option exercise | 4,000 | $6.81 |
| 2026-02-18 | Bhatt Elizabeth | President and COO | Open market sale | 2,200 | $28.46 |
| 2026-02-18 | Bhatt Elizabeth | President and COO | Open market sale | 1,800 | $29.58 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-22 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-07-15 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
Recent news
Headlines about SEPN (Septerna, Inc.). Links open the publisher — we don’t host full articles.
-
Septerna president and COO Elizabeth Bhatt sells $149,644 in stock
Investing.com · 2026-10-20 -
Form 4 Septerna Inc: Elizabeth Bhatt (President and COO) For: 15 October By Investing.com
Investing.com South Africa · 2026-10-19 -
After a $6.81 option exercise, Septerna (SEPN) COO sells 4,000 shares under a preset plan.
Stock Titan · 2026-10-19 -
Septerna Inc. (SEPN) Holds Steady Near $36 as Buyers Defend Support - Quality Factor
https://www.siam.in/ · 2026-10-19 -
How (SEPN) Movements Inform Risk Allocation Models
Stock Traders Daily · 2026-10-19 -
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
Yahoo Finance · 2026-09-14 -
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance · 2026-09-10 -
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Seeking Alpha · 2026-08-28
No headlines in this category right now — try “All”.